External validation of a radiomic signature to predict p16 (HPV) status from standard CT images of anal cancer patients
© 2023. The Author(s)..
The paper deals with the evaluation of the performance of an existing and previously validated CT based radiomic signature, developed in oropharyngeal cancer to predict human papillomavirus (HPV) status, in the context of anal cancer. For the validation in anal cancer, a dataset of 59 patients coming from two different centers was collected. The primary endpoint was HPV status according to p16 immunohistochemistry. Predefined statistical tests were performed to evaluate the performance of the model. The AUC obtained here in anal cancer is 0.68 [95% CI (0.32-1.00)] with F1 score of 0.78. This signature is TRIPOD level 4 (57%) with an RQS of 61%. This study provides proof of concept that this radiomic signature has the potential to identify a clinically relevant molecular phenotype (i.e., the HPV-ness) across multiple cancers and demonstrates potential for this radiomic signature as a CT imaging biomarker of p16 status.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Scientific reports - 13(2023), 1 vom: 03. Mai, Seite 7198 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Leijenaar, Ralph T H [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 05.05.2023 Date Revised 11.05.2023 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41598-023-34162-3 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM356412334 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM356412334 | ||
| 003 | DE-627 | ||
| 005 | 20231226210325.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41598-023-34162-3 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1187.xml |
| 035 | |a (DE-627)NLM356412334 | ||
| 035 | |a (NLM)37137947 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Leijenaar, Ralph T H |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a External validation of a radiomic signature to predict p16 (HPV) status from standard CT images of anal cancer patients |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.05.2023 | ||
| 500 | |a Date Revised 11.05.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s). | ||
| 520 | |a The paper deals with the evaluation of the performance of an existing and previously validated CT based radiomic signature, developed in oropharyngeal cancer to predict human papillomavirus (HPV) status, in the context of anal cancer. For the validation in anal cancer, a dataset of 59 patients coming from two different centers was collected. The primary endpoint was HPV status according to p16 immunohistochemistry. Predefined statistical tests were performed to evaluate the performance of the model. The AUC obtained here in anal cancer is 0.68 [95% CI (0.32-1.00)] with F1 score of 0.78. This signature is TRIPOD level 4 (57%) with an RQS of 61%. This study provides proof of concept that this radiomic signature has the potential to identify a clinically relevant molecular phenotype (i.e., the HPV-ness) across multiple cancers and demonstrates potential for this radiomic signature as a CT imaging biomarker of p16 status | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 700 | 1 | |a Walsh, Sean |e verfasserin |4 aut | |
| 700 | 1 | |a Akshayaa Vaidyanathan |e verfasserin |4 aut | |
| 700 | 1 | |a Aliboni, Lorenzo |e verfasserin |4 aut | |
| 700 | 1 | |a Sanchez, Victoria Lopez |e verfasserin |4 aut | |
| 700 | 1 | |a Leech, Michelle |e verfasserin |4 aut | |
| 700 | 1 | |a Joyce, Ronan |e verfasserin |4 aut | |
| 700 | 1 | |a Gillham, Charles |e verfasserin |4 aut | |
| 700 | 1 | |a Kridelka, Frédéric |e verfasserin |4 aut | |
| 700 | 1 | |a Hustinx, Roland |e verfasserin |4 aut | |
| 700 | 1 | |a Danthine, Denis |e verfasserin |4 aut | |
| 700 | 1 | |a Occhipinti, Mariaelena |e verfasserin |4 aut | |
| 700 | 1 | |a Vos, Wim |e verfasserin |4 aut | |
| 700 | 1 | |a Guiot, Julien |e verfasserin |4 aut | |
| 700 | 1 | |a Lambin, Philippe |e verfasserin |4 aut | |
| 700 | 1 | |a Lovinfosse, Pierre |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Scientific reports |d 2011 |g 13(2023), 1 vom: 03. Mai, Seite 7198 |w (DE-627)NLM215703936 |x 2045-2322 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2023 |g number:1 |g day:03 |g month:05 |g pages:7198 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41598-023-34162-3 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2023 |e 1 |b 03 |c 05 |h 7198 | ||